Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6164277 | 0.92 | L3MBTL1 (0.36) | L3MBTL1NOTUMPOLBMAPK9MAPK10 | |
| SCHEMBL6166867 | 0.92 | L3MBTL1 (0.36) | L3MBTL1NOTUMPOLBMAPK9MAPK10 | |
| SCHEMBL6166140 | 0.91 | L3MBTL1 (0.38) | L3MBTL1POLBRXFP1 | |
| SCHEMBL6434623 | 0.90 | NOTUM (0.39) | L3MBTL1NOTUMPOLBMAPK9MAPK10 | |
| SCHEMBL6689698 | 0.89 | L3MBTL1 (0.41) | L3MBTL1NOTUMPOLBMAPK9MAPK10 | |
| SCHEMBL6166386 | 0.89 | NOTUM (0.38) | L3MBTL1NOTUM | |
| SCHEMBL6437848 | 0.89 | NOTUM (0.43) | L3MBTL1NOTUMPOLBRORC | |
| SCHEMBL6437887 | 0.88 | PTK2 (0.39) | L3MBTL1NOTUMPOLB | |
| SCHEMBL6166873 | 0.88 | L3MBTL1 (0.42) | L3MBTL1POLBRORCRXFP1 | |
| SCHEMBL6436725 | 0.87 | TSHR (0.39) | L3MBTL1NOTUMPOLBMAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379511-B1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | HOFFMANN LA ROCHE (CH) | 2005-07-20 | — | — | EP | disclosed |
| US-6544985-B2 | For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits | HOFFMAN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | CYP1B1, GRIN2B, BDKRB1 | L3MBTL1 2727/4885NOTUM 3530/4885POLB 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.